Please assess the completion status of the following clinical trial:

Trial Title: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are male or female aged 18-55 years at the time of signing the informed consent form.~Exclusion Criteria:~* Have been treated previously with monoclonal antibody agent including any tumour necrosis factor inhibitor except SB4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SB4 (Type: EXPERIMENTAL): SB4 (etanercept) 50 mg/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).